GlassScriptPhysician profile
Mehrdad M Soroush
NPI 1033165360
$19,896.02
in general payments reported to CMS, 2019-2025
44 companies · $2,693 in 2025
The $2,693 reported for 2025 was more than what 85% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $467 · 2021: $650 · 2022: $519 · 2023: $1,048 · 2024: $2,196 · 2025: $2,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004 · Consulting Fee: $1,388 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,110 · Honoraria: $400 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.08 |
| Consulting Fee | $1,387.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,110.00 |
| Honoraria | $400.00 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $12,013.16 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Janssen Biotech, INC. | $1,818.99 | 2019-2025 | Erleada, Akeega, Carvykti |
| Pfizer INC. | $1,447.92 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $789.92 | 2019-2025 | Provenge |
| Medtronic, INC. | $514.95 | 2022-2025 | Interstim |
| Bard Peripheral Vascular, INC. | $400.00 | 2023 | |
| Karl Storz Endoscopy-America | $344.90 | 2019-2020 | |
| Abbvie INC. | $324.39 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $284.00 | 2019-2020 | |
| Tolmar, INC. | $213.56 | 2023-2025 | Jatenzo, Eligard |
| Boston Scientific Corporation | $176.43 | 2019-2024 | Lithovue, Rezum Generator |
| Astrazeneca Pharmaceuticals LP | $173.11 | 2019-2025 | Lynparza, Imfinzi |
| Teleflex LLC | $160.66 | 2023-2024 | Urolift |
| Immunitybio, INC. | $140.65 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $117.09 | 2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehrdad Soroush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.